INCLISIRAN

Brand name:

• Leqvio®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Hypercholesterolaemia

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

--

Submission sponsor:

Novartis Pharmaceuticals Australia Pty Limited

Other PBAC consideration:

• INCLISIRAN

Submission received for:

May 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 05/05/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

24/11/2023

Lodgement of required documentation:

01/12/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 14/12/2023

Status:

Finalised

Government processes:

Commenced on 05/02/2024

Medicine listed on the PBS:

01/04/2024 (see PBS schedule)

---